Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.

Rozeboom B, Dey N, De P.

Am J Cancer Res. 2019 Dec 1;9(12):2821-2831. eCollection 2019. Review.

2.

Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.

De P, Dey N.

Int J Mol Sci. 2019 Nov 15;20(22). pii: E5732. doi: 10.3390/ijms20225732. Review.

3.

RAC1 Takes the Lead in Solid Tumors.

De P, Aske JC, Dey N.

Cells. 2019 Apr 26;8(5). pii: E382. doi: 10.3390/cells8050382. Review.

4.

Decision making in precision oncology: an issue of mutational contextuality.

Dey N, De P.

Am J Cancer Res. 2019 Mar 1;9(3):628-629. eCollection 2019. No abstract available.

6.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells.

De P, Carlson JH, Leyland-Jones B, Williams C, Dey N.

Sci Rep. 2018 Sep 4;8(1):13192. doi: 10.1038/s41598-018-31575-3.

7.

Promise of Precision Medicine in Cancers: Lessons Learned.

Dey N, Williams C, Leyland-Jones B, De P.

S D Med. 2017 Nov;70(11):486-490. No abstract available.

PMID:
29088519
8.

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Dey N, Krie A, Klein J, Williams K, McMillan A, Elsey R, Sun Y, Williams C, De P, Leyland-Jones B.

Int J Mol Sci. 2017 Jun 7;18(6). pii: E1218. doi: 10.3390/ijms18061218.

9.

Mutation matters in precision medicine: A future to believe in.

Dey N, Williams C, Leyland-Jones B, De P.

Cancer Treat Rev. 2017 Apr;55:136-149. doi: 10.1016/j.ctrv.2017.03.002. Epub 2017 Mar 16. Review.

PMID:
28371665
10.

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

Dey N, De P, Leyland-Jones B.

Pharmacol Ther. 2017 Jul;175:91-106. doi: 10.1016/j.pharmthera.2017.02.037. Epub 2017 Feb 16. Review.

PMID:
28216025
11.

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.

Oncotarget. 2017 Jan 10;8(2):3072-3103. doi: 10.18632/oncotarget.13618.

12.

Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.

Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B.

Curr Opin Oncol. 2016 Nov;28(6):461-468. Review.

PMID:
27606693
13.

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N.

Oncotarget. 2016 Jul 12;7(28):43124-43149. doi: 10.18632/oncotarget.8988.

14.

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Dey N, Sun Y, Carlson JH, Wu H, Lin X, Leyland-Jones B, De P.

Am J Cancer Res. 2016 Mar 15;6(4):714-46. eCollection 2016.

15.

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Dey N, De P, Brian LJ.

Am J Transl Res. 2015 Oct 15;7(10):1675-98. eCollection 2015. Review.

16.

Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?

De P, Carlson JH, Leyland-Jones B, Dey N.

Am J Cancer Res. 2015 Aug 15;5(9):2872-91. eCollection 2015. Review.

17.

A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

Dey N, Williams C, Leyland-Jones B, De P.

Am J Transl Res. 2015 Apr 15;7(4):733-50. eCollection 2015.

18.

Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.

Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR.

Meta Gene. 2015 May 15;4:129-41. doi: 10.1016/j.mgene.2015.04.002. eCollection 2015 Jun.

19.

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Dey N, Leyland-Jones B, De P.

Am J Cancer Res. 2014 Dec 15;5(1):1-19. eCollection 2015. Review.

20.

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

De P, Carlson J, Leyland-Jones B, Dey N.

Oncotarget. 2014 Jul 15;5(13):4581-602. Review.

Supplemental Content

Loading ...
Support Center